Introduction
The acquired immune deficiency syndrome (AIDS) is now recognized as the end stage of a disease caused by human immunodeficiency virus infection (HIV, formerly LAV/HTLV-III). The Centers for Disease Control (CDC) definition of AIDS only identifies those infected individuals with certain opportunistic infections, tumours or associated diseases who have developed a progressive irreversible immune deficiency.' For every case of AIDS, it has been estimated that there are 30 to 300 individuals infected by the virus, who may exhibit acute or chronic features of the infection, or remain asymptomatic. 2 The well recognized risk groups reflect the sexual, parenteral and perinatal routes of transmission of the virus. 345 HIV is a double-stranded RNA retrovirus, which on penetration ofa susceptible cell bearing a CD4 antigen receptor (CD = cluster differentiation), makes a DNA copy of itself. This process uses a viral reverse transcriptase enzyme. This proviral DNA is then incorporated into the host genetic material where it may remain latent or periodically produce new RNA copies. New Minor opportunistic infection is common. Skin conditions encountered include a range of infections: dermatophytic fungal, viral (recalcitrant warts, herpes simplex and zoster) and bacterial (folliculitis, impetigo, and furunculosis). The spectrum of other skin disorders range from mere dryness to severe seborrhoeic dermatitis. Epstein-Barr virus may be responsible for the recently described hairy leukoplakia on the lateral borders of the tongue.'
Risk of progression to AIDS
The risk of progression to AIDS from published studies ranges from 7 to 30% over 3 to 4 years;'8 however, prospective cohort studies only represent a short period of observation from which to draw conclusions about the natural history of HIV infection. Furthermore, some of the early studies were mostly based on patients with PGL which may not be representative of all chronically infected patients. Prognostic markers for disease progression are also being sought from these studies. ' 
Pneumonia in AIDS
Pneumocystis carinji pneumonia is the commonest lifethreatening opportunistic infection in patients who progress from chronic HIV infection to AIDS. The presentation is subacute with malaise, fatigue, weight loss, and shortness of breath often developing over several weeks. Typical retrosternal or subcostal chest discomfort associated with increasing shortness of breath, a dry cough and fever finally cause the patient to seek help. The chest X-ray at presentation may be normal or show bilateral, fine infiltrates, typically perihilar. The arterial oxygen tension is usually depressed, and the carbon monoxide transfer factor, where available, is low and may be the earliest detectable abnormality. The diagnosis is confirmed by induced sputum examination or fibreoptic bronchoscopy with bronchial lavage and transbronchial biopsy, thereby leaving the patient in no doubt as to whether the full syndrome has developed. At the same time other causes of pneumonia or co-existent infection in AIDS patients such as cytomegalovirus (CMV), mycobacteria and other bacteria and fungi may be excluded. 2' Pyogenic bacterial causes of pneumonia should always be considered, particularly as their presentation may be atypical. In one series, 10% of episodes of pneumonia in AIDS patients were due to bacteria such as Streptococcus pneumoniae, Haemophilus influenzae, Branhamella and Group B Streptococci. 22 The radiological appearances may include diffuse infiltrates as well as the more typical focal or lobar patterns. Another cause of diffuse abnormality is lymphocytic interstitial pneumonitis, first described in paediatric AIDS and now increasingly recognized in adults. The cause is still uncertain, but it is certainly associated with HIV infection. Of the protozoal infections, pneumocystis is the most likely to respond well. Co-trimoxazole remains the treatment of choice. High-dose intravenous therapy (20 mg/kg/day of trimethoprim) for 3 weeks is the norm, although once the patient's fever has settled and the shortness of breath and blood gases have improved co-trimoxazole can be given orally. A minor rash during treatment may be ignored, but a very itchy generalized eruption with recurrence offever, or severe cytopaenia may occur at 7-10 days and requires a change to pentamidine mesylate. This needs to be given by slow intravenous infusion (2.5 mg/kg/day) to avoid the persistent pain and sterile abscesses that occur with intramuscular injection. Hypoglycaemia and renal failure may occur during treatment. Although unproven in controlled studies in AIDS, many physicians would follow a first attack of Pneumocystis carindi pneumonia with some form ofprophylaxis such as low dose co-trimoxazole, weekly Fansidar or monthly pentamidine.
Cryptosporidiosis may respond to spiramycin (4g/ day)38 or a combination of quinine and clindamycin, but reported success is anecdotal and spontaneous remission may occur. There are also anecdotal reports of a response to interleukin-2.39 Isosporiasis responds well to co-trimoxazole (8 tablets/day) for 10 days, but relapses occur in 50% of cases with cessation of treatment.' Cerebral toxoplasmosis responds to sulphadiazine and pyrimethamine, although delayed diagnosis and more severe symptoms are associated with a poor prognosis.
Herpes simplex virus infections respond to oral acyclovir. Prophylactic treatment (800mg/day) may be required as severe, frequent recurrences are common. Intravenous acyclovir has been used in other immunocompromised patients for the treatment of herpes zoster infection.4' It may also be given orally at a dose of 1.6 g/day. Ganciclovir (dihydroxypropoxymethyl guanine, DHPG), in uncontrolled studies, has shown promising results in the treatment of CMV retinitis and to a lesser extent pneumonia and colitis, but maintenance treatment is required and even then relapse occurs.
Simple oral candida responds initially to local nystatin or amphotericin but later may require, and responds well to, ketoconazole (200 -400 mg/day), which is also the drug of choice in oesophageal candidiasis. Cryptococcal and the rare life-threatening candidal infections required amphotericin and 5-fluorocytosine.
Bacterial pneumonias and skin infections will respond to 
